Monthly Archives: May, 2015
U.S. Food and Drug Administration Approves Eluxadoline and Rifaximin for IBS with Diarrhea
Earlier this week, on May 27, 2015, the U.S. Food and Drug Administration approved two new medications, eluxadoline (to be known by the brand name Viberzi) and rifaximin (known by the brand name Xifaxan) for use in treating irritable bowel syndrome with diarrhea in adults, 18 and older, both men and women. Both medications have …
Clinical Trials: May 2015 Open Studies for Irritable Bowel Syndrome (IBS) at UCLA
The Center for Neurobiology of Stress at UCLA, one of the major research centers involved in the research of IBS and other neurologically-based chronic pain conditions, has six varied clinical trials for irritable bowel syndrome currently seeking volunteers, Criteria, compensation and time commitment or number of visits to UCLA vary depending on the study, but …
ACTION ALERT: Functional Gastrointestinal and Motility Disorders Research Enhancement Act of 2015 (HR 2311)
On May 13, 2015, the Functional Gastrointestinal and Motility Disorders Research Enhancement Act of 2015, also known as HR 2311, was introduced in the United States House of Representatives. HR 2311 addresses public awareness efforts and research funding for functional gastrointestinal and motility disorders like IBS, as well as improved efforts at coordination of research efforts …
Clinical Trial: Oral Enzymes to Reduce Symptoms of Irritable Bowel Syndrome (IBS), Monash University, Australia 2015
Monash University in Melbourne, Australia, the original research lab to develop the low FODMAP diet, is currently seeking volunteers for a study on the use of oral enzymes to reduce galactooligosaccarides, which is one type of FODMAP. Men and women ages 18-70 who have irritable bowel syndrome, do not have any other known gastrointestinal disorder, …
IBS IMPACT 